1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Casdin Capital, LLC Buys bluebird bio Inc, Denali Therapeutics Inc, Deciphera Pharmaceuticals Inc, Sells Spark Therapeutics Inc, Sage Therapeutics Inc, Sarepta Therapeutics Inc

Investment company Casdin Capital, LLC (Current Portfolio) buys bluebird bio Inc, Denali Therapeutics Inc, Deciphera Pharmaceuticals Inc, Orchard Therapeutics PLC, Alector Inc, sells Spark Therapeutics Inc, Sage Therapeutics Inc, Sarepta Therapeutics Inc, Homology Medicines Inc, Editas Medicine Inc during the 3-months ended 2019Q4, according to the most recent filings of the investment company, Casdin Capital, LLC. As of 2019Q4, Casdin Capital, LLC owns 31 stocks with a total value of $1.1 billion. These are the details of the buys and sells.

For the details of Casdin Capital, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/casdin+capital%2C+llc/current-portfolio/portfolio

These are the top 5 holdings of Casdin Capital, LLC
  1. Sarepta Therapeutics Inc (SRPT) - 670,000 shares, 8.10% of the total portfolio. Shares reduced by 23.86%
  2. bluebird bio Inc (BLUE) - 970,000 shares, 7.98% of the total portfolio. Shares added by 58.37%
  3. Codexis Inc (CDXS) - 5,073,780 shares, 7.61% of the total portfolio.
  4. Blueprint Medicines Corp (BPMC) - 940,000 shares, 7.06% of the total portfolio.
  5. MyoKardia Inc (MYOK) - 1,005,000 shares, 6.87% of the total portfolio. Shares reduced by 9.87%
Added: bluebird bio Inc (BLUE)

Casdin Capital, LLC added to a holding in bluebird bio Inc by 58.37%. The purchase prices were between $72.5 and $95.22, with an estimated average price of $83.99. The stock is now traded at around $89.31. The impact to a portfolio due to this purchase was 2.94%. The holding were 970,000 shares as of .

Added: Denali Therapeutics Inc (DNLI)

Casdin Capital, LLC added to a holding in Denali Therapeutics Inc by 92.31%. The purchase prices were between $14.4 and $19.99, with an estimated average price of $16.72. The stock is now traded at around $25.42. The impact to a portfolio due to this purchase was 0.98%. The holding were 1,250,000 shares as of .

Added: Deciphera Pharmaceuticals Inc (DCPH)

Casdin Capital, LLC added to a holding in Deciphera Pharmaceuticals Inc by 155.00%. The purchase prices were between $31.7 and $69.93, with an estimated average price of $48.06. The stock is now traded at around $55.54. The impact to a portfolio due to this purchase was 0.91%. The holding were 255,000 shares as of .

Added: Orchard Therapeutics PLC (ORTX)

Casdin Capital, LLC added to a holding in Orchard Therapeutics PLC by 164.52%. The purchase prices were between $10.15 and $15.58, with an estimated average price of $12.21. The stock is now traded at around $12.60. The impact to a portfolio due to this purchase was 0.66%. The holding were 820,000 shares as of .

Added: Alector Inc (ALEC)

Casdin Capital, LLC added to a holding in Alector Inc by 32.67%. The purchase prices were between $14.17 and $20.3, with an estimated average price of $17.11. The stock is now traded at around $30.00. The impact to a portfolio due to this purchase was 0.43%. The holding were 1,076,039 shares as of .

Added: Gritstone Oncology Inc (GRTS)

Casdin Capital, LLC added to a holding in Gritstone Oncology Inc by 22.03%. The purchase prices were between $7.07 and $11.61, with an estimated average price of $8.35. The stock is now traded at around $9.47. The impact to a portfolio due to this purchase was 0.33%. The holding were 2,160,000 shares as of .

Sold Out: Spark Therapeutics Inc (ONCE)

Casdin Capital, LLC sold out a holding in Spark Therapeutics Inc. The sale prices were between $96.25 and $113.57, with an estimated average price of $107.51.

Sold Out: Homology Medicines Inc (FIXX)

Casdin Capital, LLC sold out a holding in Homology Medicines Inc. The sale prices were between $11.42 and $22.19, with an estimated average price of $15.98.

Sold Out: Editas Medicine Inc (EDIT)

Casdin Capital, LLC sold out a holding in Editas Medicine Inc. The sale prices were between $19.49 and $32.63, with an estimated average price of $25.2.



Here is the complete portfolio of Casdin Capital, LLC. Also check out:

1. Casdin Capital, LLC's Undervalued Stocks
2. Casdin Capital, LLC's Top Growth Companies, and
3. Casdin Capital, LLC's High Yield stocks
4. Stocks that Casdin Capital, LLC keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)